Techniques in Vascular & Interventional Radiology
Volume 9, Issue 2 , Pages 50-55 , June 2006

Management of Dyslipidemia with Statins in the Patient with Peripheral Arterial Disease

  • Andrew S. Blum, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Andrew S. Blum, MD, Division of Vascular Interventional Radiology, Elmhurst Memorial Hospital, 200 Berteau Avenue, Elmhurst, Illinois 60126.

References 

  1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  2. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc. 1997;45:1472–1478
  3. Hankey GJ, Norman PE, Eikelbloom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547–553
  4. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  6. The Lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–364
  7. Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery. 1996;120:672-379
  8. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipolniacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438–447
  9. Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Med Scand. 1985;701(suppl):53–57
  10. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1999;282:2051–2057
  11. Shepard J, Cobb SM, Ford I, et al. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  12. Sacks FM, Pfeffer MA, Moye IA, et al. Cholesterol and Recurrent Events Trial Investigators The effect if pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  13. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  14. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–392
  15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  16. Grundy SM, Cleeman JI, Bairey CN, et al. Implications of recent clinical trials for the national cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  17. Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  18. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  19. Ridker PM, Plutzky J. Statins for stroke: the second story. Circulation. 2001;103:348–350
  20. Davignon J. Beneficial cardiovascular pleiotrophic effects of statins. Circulation. 2004;109:39–43
  21. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atovastatin Diabetes Study (CARDS). Lancet. 2004;364:685-396
  22. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  23. LaRosa JC, Grundy SM, Waters DD, et al. Treating to new targets (TNT) investigators (Intensive lipid lowering with atorvastatin in patients with stable coronary disease). N Engl J Med. 2005;352:1425–1435
  24. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080
  25. Nissen SE, Nicholls SJ, Sipahl I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565
  26. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  27. Pasternak RC, Smith SC, Bailey-Merz C, et al. ACC/AHA/NHLBI clinical advisory use and safety of statins. Circulation. 2002;106:1024–1028
  28. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4:34–41
  29. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690
  30. Nawarskas J. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev. 2005;13:76–79
  31. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24:258–272
  32. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120–122
  33. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Final report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart Blood and Lung Institute Vol. 2004, 2002
  34. Wortmann RL. Lipid lowering agents and myopathy. Curr Opin Rheumatol. 2002;14:643–647
  35. Gotto AM. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med. 2003;163:657–659
  36. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–1948
  37. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775–1781
  38. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155
  39. Price JF, Lee AJ, Rumley A, et al. Lipoprotein(a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis. 2001;157:241–249
  40. Valentine RJ, Grayburn PA, Vega GL, et al. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med. 1994;154:801–806
  41. Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med. 1992;232:349–352
  42. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc. 2001;285:2481–2485

PII: S1089-2516(06)00048-5

doi: 10.1053/j.tvir.2006.12.004

Techniques in Vascular & Interventional Radiology
Volume 9, Issue 2 , Pages 50-55 , June 2006

Article Tools